Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
INCB009471 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Treatment A - INCB009471 100mg IR | EXPERIMENTAL | INCB009471, 100 mg IR orally once daily |
| Treatment B - INCB009471 300mg SR | EXPERIMENTAL | INCB009471, 300 mg SR orally once daily |
| Treatment C - Placebo | PLACEBO_COMPARATOR | Placebo matching INCB009471 |
| Name | Type | Description |
|---|---|---|
| INCB009471 | DRUG | 100mg SR (sustained release) orally once daily |
| Placebo comparator | DRUG | Orally once daily |
Inclusion Criteria: Asymptomatic HIV-1 infected individuals that are treatmen naïve (ie less than 2 weeks prior ARV exposure) or treatment experienced subjects who are not currently on HAART and have not received any ARVs for 3 months prior to Screening. * Males between 18 years and 65 years of ag...
Top 20 of 28 competitors
INCB009471 is an investigational small molecule being studied for the treatment of HIV Infections. It is a chemokine coreceptor 5 (CCR5) antagonist, meaning it targets the CCR5 receptor to potentially block viral entry. The drug is currently in Phase 2 clinical development and is not yet approved by regulatory authorities.
INCB009471 targets the chemokine coreceptor 5 (CCR5), a protein on the surface of certain immune cells that HIV uses to enter and infect cells. By blocking CCR5, the drug aims to prevent the virus from entering cells, which is a potential strategy for treating HIV infections.
INCB009471 is being developed by Incyte Corporation, a biopharmaceutical company traded on the NASDAQ under the ticker symbol INCY. The company is conducting clinical research on this investigational drug for the treatment of HIV Infections.
INCB009471 is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by the FDA or other regulatory agencies. The drug is being studied for safety and effectiveness in patients with HIV Infections, and its clinical development is ongoing.
INCB009471 has one completed Phase 2 clinical trial, identified by the National Clinical Trial number NCT00393120. This trial, titled "Safety/Effectiveness of Oral Chemokine Coreceptor 5 (CCR5) Antagonist INCB009471 in R5-tropic HIV Infected Patients," enrolled 45 participants in the United States. The study was randomized, double-blind, and placebo-controlled.
Yes, INCB009471 is a CCR5 antagonist. It is designed to block the chemokine coreceptor 5 (CCR5), which is a key entry point for HIV into cells. This mechanism is being investigated as a potential treatment for HIV Infections in a Phase 2 clinical trial.